Strs Ohio Buys Shares of 512,180 Gilead Sciences, Inc. $GILD

Key Points

• Strs Ohio acquired a stake of 512,180 shares in Gilead Sciences, Inc., valued at approximately $57.39 million, as detailed in its 1st quarter 13F filing.
• The company reported $2.01 earnings per share for the last quarter, surpassing analysts' expectations, with revenues of $7.08 billion.
• Gilead Sciences declared a quarterly dividend of $0.79 per share, with a dividend yield of 2.7%, to be paid on September 29th.

Strs Ohio bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 512,180 shares of the biopharmaceutical company's stock, valued at approximately $57,390,000.

Several other large investors also recently added to or reduced their stakes in GILD. McAdam LLC grew its holdings in shares of Gilead Sciences by 3.9% during the 1st quarter. McAdam LLC now owns 26,353 shares of the biopharmaceutical company's stock worth $2,953,000 after purchasing an additional 981 shares during the period. Acadian Asset Management LLC grew its holdings in shares of Gilead Sciences by 92.1% during the 1st quarter. Acadian Asset Management LLC now owns 395,480 shares of the biopharmaceutical company's stock worth $44,300,000 after purchasing an additional 189,569 shares during the period. IFM Investors Pty Ltd grew its holdings in shares of Gilead Sciences by 2.0% during the 1st quarter. IFM Investors Pty Ltd now owns 254,029 shares of the biopharmaceutical company's stock worth $28,464,000 after purchasing an additional 5,079 shares during the period. Focus Partners Wealth grew its holdings in shares of Gilead Sciences by 21.2% during the 1st quarter. Focus Partners Wealth now owns 142,666 shares of the biopharmaceutical company's stock worth $15,986,000 after purchasing an additional 24,930 shares during the period. Finally, Integrity Alliance LLC. purchased a new position in shares of Gilead Sciences during the 1st quarter worth $210,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

GILD stock opened at $115.25 on Thursday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The firm has a market capitalization of $143.00 billion, a P/E ratio of 22.96, a P/E/G ratio of 0.78 and a beta of 0.36. The business's 50-day moving average is $113.84 and its two-hundred day moving average is $110.02. Gilead Sciences, Inc. has a 1 year low of $79.64 and a 1 year high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter last year, the company earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be given a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences's dividend payout ratio (DPR) is currently 62.95%.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the sale, the insider owned 114,168 shares of the company's stock, valued at $13,532,333.04. This trade represents a 19.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $296,325.00. Following the sale, the chief financial officer directly owned 160,110 shares in the company, valued at $18,977,838.30. This trade represents a 1.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock worth $9,371,330 over the last 90 days. 0.27% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on GILD shares. Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and increased their price target for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a research note on Friday, July 25th. Royal Bank Of Canada increased their target price on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research note on Friday, August 8th. Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Finally, UBS Group increased their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research note on Friday, August 8th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $115.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.